Enterocolitis – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Enterocolitis – Pipeline Review, H2 2017’, provides an overview of the Enterocolitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Enterocolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Enterocolitis

The report reviews pipeline therapeutics for Enterocolitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Enterocolitis therapeutics and enlists all their major and minor projects

The report assesses Enterocolitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Enterocolitis

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Enterocolitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Enterocolitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AvidBiotics Corp

Infant Bacterial Therapeutics AB

Leadiant Biosciences Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Enterocolitis - Overview 6

Enterocolitis - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 11

Enterocolitis - Therapeutics Assessment 12

Assessment by Target 12

Assessment by Mechanism of Action 14

Assessment by Route of Administration 16

Assessment by Molecule Type 17

Enterocolitis - Companies Involved in Therapeutics Development 19

AvidBiotics Corp 19

Infant Bacterial Therapeutics AB 19

Leadiant Biosciences Inc 20

Enterocolitis - Drug Profiles 21

AvR-2V10 - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

C-34 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

IBP-9414 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

melatonin - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

NRG-4 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Small Molecule for Infectious Diarrhea and Necrotizing Enterocolitis - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Small Molecules for Necrotizing Enterocolitis - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

STP-206 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Enterocolitis - Dormant Projects 31

Enterocolitis - Product Development Milestones 32

Featured News & Press Releases 32

Sep 28, 2017: European Medicines Agency adopts a positive opinion on the Paediatric Investigation Plan for IBT’s lead product 32

Sep 11, 2017: Infant Bacterial Therapeutics announces that top line data demonstrate similar safety and tolerability profile in the active and placebo groups 32

Jan 24, 2017: Last patient enrolled in IBT's Phase 2 study 32

Nov 21, 2016: Positive recommendation from the independent Data Safety Monitoring Board to continue Phase II Study 33

Jun 07, 2016: Infant Bacterial Therapeutics enrolls First Patient in Phase 2 Clinical Trial 33

Mar 31, 2016: IBT receives Rare Pediatric Disease Designation from FDA for drug candidate 33

Jan 08, 2016: BioGaia’s subsidiary IBT has US IND open and Swedish CTA approved for clinical study 33

Jun 24, 2015: BioGaia Subsidiary IBT Takes Rapid Steps in Development of a Drug for Premature Infants 34

Jun 12, 2015: BioGaia evaluates the possibility of a separate listing of Infant Bacterial Therapeutics 34

Mar 26, 2015: Infant Bacterial Therapeutics receives additional funding from mother company BioGaia 35

Feb 23, 2015: BioGaia subsidiary Infant Bacterial Therapeutics gets Orphan Drug Designation in Europe 35

Feb 21, 2014: FDA approves orphan drug designation for IBP-9414 35

Appendix 36

Methodology 36

Coverage 36

Secondary Research 36

Primary Research 36

Expert Panel Validation 36

Contact Us 36

Disclaimer 37

List of Tables

List of Tables

Number of Products under Development for Enterocolitis, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products under Development by Universities/Institutes, H2 2017 9

Products under Development by Companies, H2 2017 10

Products under Development by Universities/Institutes, H2 2017 11

Number of Products by Stage and Target, H2 2017 13

Number of Products by Stage and Mechanism of Action, H2 2017 15

Number of Products by Stage and Route of Administration, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 18

Enterocolitis – Pipeline by AvidBiotics Corp, H2 2017 19

Enterocolitis – Pipeline by Infant Bacterial Therapeutics AB, H2 2017 19

Enterocolitis – Pipeline by Leadiant Biosciences Inc, H2 2017 20

Enterocolitis – Dormant Projects, H2 2017 31

List of Figures

List of Figures

Number of Products under Development for Enterocolitis, H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products by Targets, H2 2017 12

Number of Products by Stage and Targets, H2 2017 12

Number of Products by Mechanism of Actions, H2 2017 14

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Stage and Routes of Administration, H2 2017 16

Number of Products by Molecule Types, H2 2017 17

Number of Products by Stage and Molecule Types, H2 2017 17

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports